Navigation Links
Haemonetics Reports Third Quarter of Fiscal 11
Date:1/31/2011

usiness are accelerating driven by the Company's IMPACT accounts.  Haemonetics expects full year revenue growth of approximately 25%.  

Software Solutions revenue was $16.6 million for the quarter, up 101%, and $49.2 million year to date, up 90%.  Software Solutions growth was primarily impacted by our Global Med acquisition.  Organic software growth was 14% in the quarter and 6% year to date.  Haemonetics expects full year revenue growth of approximately 95%.

Equipment and Other revenue was $16.1 million for the quarter, up 16%, and $43.3 million year to date, up 22%.  Year to date equipment growth was impacted by the SEBRA® acquisition.  Organic equipment growth year to date was 14%.  Haemonetics expects full year revenue growth of 5-8% as we compare to Q4 fiscal 10 Equipment and Other sales of $18.8 million which included $2.5 million of one-time royalty revenue.

In the quarter, North American sales were up 6%, European sales were up 10%, Japanese sales were down 3%, and Asian sales were up 22%.  Year to date, North American sales were up 6%, European sales were up 6%, Japanese sales were up 1% and Asian sales were up 26%.

CONFERENCE CALLHaemonetics will host a webcast on Monday, January 31st at 10:00am Eastern to discuss these results.  Interested parties can participate at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=3643178

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers.  Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes a
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
2. Neogen Reports 33% Increase in Net Income
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. New Topical Patent Research Reports Recently Published at MarketPublishers.com
5. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
6. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
7. GeneLink Reports Third Quarter Results
8. Imagenetix, Inc. Reports Second Quarter 2011 Results
9. Transgenomic Reports Third Quarter Financial Results
10. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... DIEGO , Aug. 31, 2015 MabVax ... development company announces that the Company,s lead antibody, HuMab ... of five separate presentations during the upcoming World Molecular ... September 2-5, 2015. Researchers from the Department ... will present results on the use of MabVax,s lead ...
(Date:8/31/2015)... -- For people with Down syndrome, news from Elixirgen, ... located in the Science + Technology Park at Johns ... yet for people with Down syndrome and other chromosome disorders ... and Edwards syndrome aneuploidies in human cell cultures, " ... plans to develop this technology into a treatment for ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, Inc., ... of novel cancer immunotherapies, announced today that it has ... Executive Officer and William Ho , M.D., Ph.D., ... an experienced management team led by veterans of Flexus ... Ph.D., Chief Scientific Officer; Jay Powers , Ph.D., ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option ... the first commercially available new FDA approved system in the last 14 years, and ... the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced financial results ... The net loss for the fourth quarter ended December 31, ... period in 2009. The net loss for the year ended December ... year ended December 31, 2009.   The increase in net loss ...
... at North Carolina State University have developed a ... their alignment and density. The researchers hope the ... of device applications using nanowires, from nanoelectronics to ... plastic and paper. "Alignment is a critical ...
... HONG KONG, Feb. 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood ... China,s leading provider of cord blood collection, laboratory testing, hematopoietic ... unaudited financial results for the third quarter and first nine ... Third Quarter of Fiscal ...
Cached Biology Technology:MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 2MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 3MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 4MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 5MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 6MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 7Stretched rubber offers simpler method for assembling nanowires 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 11
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... at several sites in Pacific Ocean waters off the ... This study is the first to look at caffeine ... conducted by Portland State University master,s student Zoe Rodriguez ... professor of Environmental Science and Management, in collaboration with ...
... of carbon dioxide (CO 2 ) the main cause of ... high of 34 billion tonnes in 2011. In China, the world,s ... 9% to 7.2 tonnes per capita. China is now within the ... major industrialised countries. In the European Union, CO 2 emissions ...
... meeting of the Society for Neuroscience, is the world,s largest ... Learn how the brain works and new developments on ... mental illness, among others. More than 16,000 new discoveries ... world. , Credentialed media can access press conferences and ...
Cached Biology News:PSU study finds 'caffeinated' coastal waters 2Global CO2 emissions continue to increase 2Media registration opens for Neuroscience 2012, world's largest brain science meeting 2
Human Glypican 2 Biotinylated Affinity Purified PAb...
B2-Microgloulin...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
...
Biology Products: